New MS Drug Reduces Flare-Ups

In clinical trials, the new drug, BG-12, has been shown to lower the number of nerve cell attacks with fewer side effects. It is expected to cost about $50,000 a year, the same as other similar drugs. NBC’s Robert Bazell reports.